LENZ vs. ARES

Last updated Jun 24, 2026

LENZ (LENZ Therapeutics Inc) and ARES (Ares Management Corporation) are both stocks. LENZ operates in Biotechnology (Healthcare), while ARES operates in Asset Management (Financial Services). Over the past 3 years, LENZ returned -13.43%/yr vs 13.92%/yr for ARES. At a 0.24 correlation, their price movements are largely independent.

Performance

LENZ vs. ARES - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in LENZ Therapeutics Inc (LENZ) and Ares Management Corporation (ARES). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, LENZ achieves a -64.06% return, which is significantly lower than ARES's -23.01% return.

LENZ

• 1D: -1.20%
• 1M: -23.84%
• YTD: -64.06%
• 6M: -65.96%
• 1Y: -81.14%
• 3Y*: -13.43%
• 5Y*: —
• 10Y*: —

ARES

• 1D: -4.07%
• 1M: -1.32%
• YTD: -23.01%
• 6M: -26.26%
• 1Y: -23.41%
• 3Y*: 13.92%
• 5Y*: 18.72%
• 10Y*: 29.90%

*Multi-year figures are annualized to reflect compound growth (CAGR)

LENZ vs. ARES - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
LENZ LENZ Therapeutics Inc	-64.06%	-44.58%	230.71%	-21.08%	-73.29%	-43.76%
ARES Ares Management Corporation	-23.01%	-5.72%	52.68%	79.52%	-12.75%	35.85%

Correlation

The correlation between LENZ and ARES is 0.13, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.13
Correlation (3Y) Calculated over the trailing 3-year period	0.16
Correlation (All Time) Calculated using the full available price history since Jun 25, 2021	0.24

The correlation between LENZ and ARES shifts across timeframes, from 0.13 (1 year) to 0.24 (all time), reflecting how their relationship changes across market environments.

Fundamentals

EPS LENZ : -$3.66 ARES : $2.83
PS Ratio LENZ : 8.15 ARES : 4.21
Total Revenue (TTM) LENZ : $20.99M ARES : $6.31B
Gross Profit (TTM) LENZ : $19.37M ARES : $4.46B
EBITDA (TTM) LENZ : -$116.01M ARES : $2.42B

Return for Risk

LENZ vs. ARES — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LENZ

LENZ Risk / Return Rank: 5
LENZ Sharpe Ratio Rank: 5
LENZ Sortino Ratio Rank: 3
LENZ Omega Ratio Rank: 3
LENZ Calmar Ratio Rank: 6
LENZ Martin Ratio Rank: 8

ARES

ARES Risk / Return Rank: 21
ARES Sharpe Ratio Rank: 18
ARES Sortino Ratio Rank: 19
ARES Omega Ratio Rank: 19
ARES Calmar Ratio Rank: 26
ARES Martin Ratio Rank: 24

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LENZ vs. ARES - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for LENZ Therapeutics Inc (LENZ) and Ares Management Corporation (ARES). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	LENZ	ARES	Difference
Sharpe ratio: Return per unit of total volatility	-1.01	-0.56	-0.45
Sortino ratio: Return per unit of downside risk	-2.05	-0.57	-1.49
Omega ratio: Gain probability vs. loss probability	0.75	0.93	-0.18
Calmar ratio: Return relative to maximum drawdown	-0.92	-0.48	-0.44
Martin ratio: Return relative to average drawdown	-1.41	-0.92	-0.48

LENZ vs. ARES - Sharpe Ratio Comparison

The current LENZ Sharpe Ratio is -1.01, which is lower than the ARES Sharpe Ratio of -0.56. The chart below compares the historical Sharpe Ratios of LENZ and ARES, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

LENZ vs. ARES - Drawdown Comparison

The maximum LENZ drawdown since its inception was -94.38%, which is greater than ARES's maximum drawdown of -49.73%. Use the drawdown chart below to compare losses from any high point for LENZ and ARES.

Drawdown Indicators

	LENZ	ARES	Difference
Max Drawdown Largest peak-to-trough decline	-94.38%	-49.73%	-44.65%
Max Drawdown (1Y) Largest decline over 1 year	-88.28%	-49.05%	-39.23%
Max Drawdown (3Y) Largest decline over 3 years	-88.28%	-49.73%	-38.55%
Max Drawdown (5Y) Largest decline over 5 years	-94.38%	-49.73%	-44.65%
Max Drawdown (10Y) Largest decline over 10 years	—	-49.73%	—
Current Drawdown Current decline from peak	-94.38%	-35.17%	-59.21%
Average Drawdown Average peak-to-trough decline	-78.72%	-11.36%	-67.36%
Ulcer Index Depth and duration of drawdowns from previous peaks	57.67%	25.42%	+32.25%

Volatility

LENZ vs. ARES - Volatility Comparison

LENZ Therapeutics Inc (LENZ) and Ares Management Corporation (ARES) have volatilities of 12.51% and 12.55%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	LENZ	ARES	Difference
Volatility (1M) Calculated over the trailing 1-month period	12.51%	12.55%	-0.04%
Volatility (6M) Calculated over the trailing 6-month period	54.83%	35.66%	+19.17%
Volatility (1Y) Calculated over the trailing 1-year period	80.50%	41.79%	+38.71%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	77.33%	37.52%	+39.81%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	77.33%	36.74%	+40.59%

Dividends

LENZ vs. ARES - Dividend Comparison

LENZ has not paid dividends to shareholders, while ARES's dividend yield for the trailing twelve months is around 5.49%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
ARES Ares Management Corporation	5.49%	3.29%	2.10%	2.59%	3.57%	2.31%	3.40%	3.59%	7.50%	5.65%	4.32%	6.81%
LENZ LENZ Therapeutics Inc	0.00%	0.00%	28.54%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

Frequently Asked Questions

Can I hold both LENZ and ARES in my portfolio?

LENZ and ARES have a correlation of 0.13, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, LENZ or ARES?

ARES has higher volatility (12.55%) compared to LENZ (12.51%). In terms of maximum drawdown, LENZ dropped -94.38% vs ARES's -49.73%.

Which has better risk-adjusted returns?

ARES currently has the higher Sharpe Ratio (-0.56 vs -1.01), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.